ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0897

Age-Stratified Trend of Spinal Radiographic Damage Progression in Patients with Ankylosing Spondylitis
Abstract Number: 0898

MRI Vertebral Corner Inflammation and Fat Deposition Are Associated with Whole Spine Low Dose CT Detected Syndesmophytes: A Multilevel Analysis
Abstract Number: 0899

Comparison of Sacroiliac CT Findings in Patients with and Without Ankylosing Spondylitis Aged 50 Years or Older: Preliminary Results of the CASIAGE Study
Abstract Number: 0900

The Phenomenon of Fused Sacroiliac Joints but Absent Syndesmophytes in Long Standing Ankylosing Spondylitis Patients: Data from a Prospectively Followed Cohort
Abstract Number: 0901

Low Dose Dual Energy CT Scan for the Detection of Bone Marrow Edema and Erosions in Axial Spondyloarthritis
Abstract Number: 0902

Does Imaging of the Sacroiliac Joint and Spine Differ in Patients Presenting with Undiagnosed Back Pain and Psoriasis, Acute Anterior Uveitis, and Colitis: An Inception Cohort Study
Abstract Number: 0903

Scoring MRI Structural Lesions in Sacroiliac Joints of Patients with Axial Spondyloarthritis: How Many Slices Are Optimal?
Abstract Number: 0904

Data-driven Definitions Based on Inflammatory Lesions for a Positive MRI of the Spine Consistent with Axial Spondyloarthritis
Abstract Number: 0905

Artificial Neural Network for the Recognition of Active Inflammatory Changes Compatible with Axial Spondyloarthritis on Magnetic Resonance Imaging of Sacroiliac Joints
Abstract Number: 0906

Measurement of Vertebral Hounsfield Units in Low Dose Computed Tomography – a Reliable Methodology for Assessing Bone Mineral Density at the Vertebral Level in Patients with Radiographic Axial Spondyloarthritis
Abstract Number: 0907

Radiographic Sacroiliitis Progression up to Six Years of Follow-Up in Patients with Non-Radiographic Axial Apondyloarthritis
Abstract Number: 0908

Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study
Abstract Number: 0909

How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Abstract Number: 0910

The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing Spondylitis: Data from the PSOAS Cohort
Abstract Number: 0911

Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].